Infectious
|
Lower respiratory tract illness (e.g., pneumonia) |
Septic emboli from bacteremia |
Sepsis |
Aspiration pneumonia |
Aspiration pneumonitis |
Post-obstructive pneumonia (particulary in setting of an obstructing malignancy) |
Cardiac
|
Acute myocardial infarction (AMI) |
Congestive heart failure (CHF) with pulmonary edema |
Chronic |
Acute e.g., due to AMI or acute valvular insufficiency |
Cardiac toxicity from prior therapy, including |
Cyclophosphamide |
Mitoxantrone |
Anthracyclines |
Paclitaxel and docetaxel |
Trastuzumab |
Mediastinal or total body irradiation |
Pulmonary
|
Noncardiogenic pulmonary edema |
Volume overload |
Capillary leak (e.g., sepsis) |
Pulmonary embolism (particularly with infarction) |
Fat embolism |
Transfusion-related lung injury |
Alveolar hemorrhage |
Idiopathic eosinophilic pneumonia |
ARDS |
Preexisting pulmonary disease (e.g., COPD, bronchiectasis) |
Preexisting medical disease (e.g., rheumatoid arthritis) |
Medication related (e.g., amiodarone) |
Oncological
|
Metatstatic malignancy |
Primary lung malignancy |
Leukemic infiltrates |
Treatment-Related Pulmonary Toxicity
|
Radiation-induced pneumonitis and fibrosis |
Medication related, including |
Bleomycin |
Busulfan |
Chorambucil |
Cyclophosphamide |
Gefitinib |
Methotrexate |
Nitrosoureas |
Procarbazine |
Rituximab |
Taxanes |
mTor inhibitor-associated pneumonitis |
Others |
Cryptogenic organizing pneumonia (COP) (bronchiolitis obliterans organizing pneumonia, BOOP) |
After stem cell or bone marrow transplantation
|
Idiopathic pneumonia syndrome (idiopathic interstitial pneumonitis) |
Graft versus host disease (GVHD) |